New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC). Background: KRAS mutated CRC ...
Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...
By activating the EGF/EGFR signaling pathway and downstream cascades, such as Src/PI3K/Akt/mTOR, it may be possible to enhance the motility and proliferative capacity of oral keratinocytes during ex ...
Clinical relevance of insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression.
Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. Background: Insulin and insulin-like growth factors are key regulators of normal metabolism and ...
Suresh Ramalingam, MD, FACP, FASCO, a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, is the executive director of the Winship Cancer Institute ...
It has been previously demonstrated that B7-H3 and EGFR are co-expressed in multiple solid tumors. At the ongoing AACR meeting in San Diego, researchers from Innovent Biologics Inc. presented ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results